

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

Barnaby Hunt  · Michelle Mocarski · William J. Valentine · Jakob Langer

Published online: May 18, 2017
© The Author(s) 2017. This article is an open access publication

Erratum to: Adv Ther (2017) 34:954–965
DOI 10.1007/s12325-017-0502-2

In the original publication, Figure 3 was published incorrectly with errors. In Fig. 3, the “Not defined*” labels should appear in the ‘Insulin Glargine U100’ row of the table beneath the figure. In place of these the values ‘41,530’ and ‘57,642’, respectively, should appear in the IDegLira row of the table beneath the figure. It has been corrected and the correct version is provided below.

The online version of the original article can be found under doi:[10.1007/s12325-017-0502-2](https://doi.org/10.1007/s12325-017-0502-2).

B. Hunt (✉) · W. J. Valentine
Ossian Health Economics and Communications,
Basel, Switzerland
e-mail: hunt@ossianconsulting.com

M. Mocarski
Novo Nordisk Inc., Plainsboro, NJ, USA

J. Langer
Novo Nordisk A/S, Søborg, Denmark




Fig. 3 Cost of control: patients with HbA1c >9.0% at baseline. \$, 2015 US dollars; HbA1c, glycated hemoglobin. *Cost of control values cannot be calculated in the insulin glargine U100 arm for HbA1c ≤6.5% without weight gain

and HbA1c ≤6.5% without confirmed hypoglycemia and weight gain, as no patients in the insulin glargine U100 arm achieved these treatment targets

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any

medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.